Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566334 | 0.84 | MAPT (0.58) | NCF1LOXL2KDM4EMAPTCYP3A4 | |
| SCHEMBL20019491 | 0.80 | KDM4E (0.42) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL28341049 | 0.76 | LMNA (0.56) | NCF1HTR1AKDM4EMAPTCYP3A4 | |
| SCHEMBL27917128 | 0.75 | CYP1A2 (0.60) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL1227713 | 0.75 | CYP1A2 (0.60) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL29699887 | 0.75 | CYP1A2 (0.60) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL30487734 | 0.73 | CYP1A2 (0.58) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL134737 | 0.73 | NCF1 (0.58) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL18574397 | 0.73 | CCNC (0.39) | NCF1KDM4EMAPT | |
| SCHEMBL17059461 | 0.73 | PARP1 (0.47) | NCF1LOXL2HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242957-B2 | Kinetic hydrate inhibitors for controlling gas hydrate formation in wet gas systems | CHAMPIONX USA INC. (US) | 2022-02-08 | — | — | US | claimed |
| CN-108530241-B | Preparation method of benzo ring derivative with benzyl quaternary carbon center | 武汉大学 | 2021-02-02 | — | — | CN | claimed |
| US-20190353307-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | HARBISON-FISCHER, INC. | 2019-11-21 | — | — | US | claimed |
| EP-3420055-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | Ecolab USA Inc. (US) | 2019-01-02 | — | — | EP | claimed |
| WO-2017147426-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | ECOLAB USA INC. (US) | 2017-08-31 | — | — | WO | claimed |
| US-20170248276-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | US SYNTHETIC CORPORATION | 2017-08-31 | — | — | US | claimed |
| CN-1250540-C | Improved single-reactor synthesis of [2,8-di(trifluoromethyl)-4-quinolyl]-2-pyridyl methyl ketone and methylfluoro quine | NAT PHARMACEUTICAL EDUCATION A (IN) | 2006-04-12 | — | — | CN | claimed |
| CN-1370777-A | Improved single-reactor synthesis of [2,8-di(trifluoromethyl)-4-quinolyl]-2-pyridyl methyl ketone and methylfluoro quine | NAT PHARMACEUTICAL EDUCATION A (IN) | 2002-09-25 | — | — | CN | claimed |
| EP-3420055-B1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | CHAMPIONX LLC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4063368-B1 | NITROGEN-CONTAINING COMPOUND AND ELECTRONIC ELEMENT COMPRISING SAME, AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MAT CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| EP-4328285-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| CN-114213441-B | Boron or phosphorus fused ring compound, preparation method thereof and light-emitting device | 中国科学院长春应用化学研究所 | 2023-12-01 | — | — | CN | disclosed |
| US-11825740-B2 | Amine compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| EP-2139880-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009062285-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062289-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009019286-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008116831-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | GPX1, LAGE3, NFE2L2 | NCF1 1350/4885LOXL2 571/4885HTR1A 3903/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | NCF1 1174/4885LOXL2 3142/4885HTR1A 4058/4885 |
| US-11825740-B2 | Amine compound and organic light-emitting device including the same | AOC2, AOC1, AOC3 | NCF1 2107/4885LOXL2 112/4885HTR1A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.